Abstract
Stepwise modification of ovatodiolide revealed a prodrug, NMP-diepoxyovatodiolide, which can provide sustained release of an active compound, substantial metabolic stability and a unique accumulation profile in the liver. Besides, NMP-diepoxyovatodiolide demonstrated therapeutic benefits in an acute autoimmune hepatitis mouse model and a broad safety window. Therefore, NMP-diepoxyovatodiolide is a very promising candidate for further development of liver-related drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 11018-11021 |
| Number of pages | 4 |
| Journal | Chemical Communications |
| Volume | 56 |
| Issue number | 75 |
| DOIs | |
| Publication status | Published - 25 Sept 2020 |
| Externally published | Yes |